Pharmaceutical group · United States

Mirum

United States22 medicines5 countries

A group of 5 companies with 22 medicines in 5 countries.

Website Its medicines

Group structure

5 companies in 2 countries

United States2

Netherlands1

Mirum Pharmaceuticals International B.V.Authorisation holder · 12 medicines

Headquarters not stated2

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine of every company in the group, current ones first.

22 medicines

Medicine	Substance	Country	Status	Authorised
CHOLBAM250mg \| 50mg · Capsule	Cholic acid	United States	Marketed	2015
CTEXLI250mg · Tablet	Chenodiol	United States	Marketed	2025
LIVMARLI20 mg · Tablet	Maralixibat chloride	Canada	Marketed	2026
LIVMARLI10 mg · Tablet	Maralixibat chloride	Canada	Marketed	2026
LIVMARLI15 mg · Tablet	Maralixibat chloride	Canada	Marketed	2026
LIVMARLI19 mg / ml · Solution	Maralixibat chloride	Canada	Marketed	2026
LIVMARLI30 mg · Tablet	Maralixibat chloride	Canada	Marketed	2026
Livmarli	Maralixibat chloride	EU (EMA)	Authorised	2022
LIVMARLI10mg base \| 15mg base \| 20mg base \| 30mg base · Tablet	Maralixibat chloride	United States	Marketed	2025
LIVMARLI9.5 mg / ml · Solution	Maralixibat chloride	Canada	Marketed	2023
LIVMARLI19mg base/ml \| 9.5mg base/ml · Solution	Maralixibat chloride	United States	Marketed	2021
LIVMARLI 10 MG COMPRIMIDOS10,53 mg · Comprimido	Maralixibat chloride	Spain	Authorised	2026
Livmarli 10 mg, tablettenTablet	Maralixibat chloride	Netherlands	Authorised	2022
LIVMARLI 15 MG COMPRIMIDOS10,53 mg · Comprimido	Maralixibat chloride	Spain	Authorised	2026
Livmarli 15 mg, tablettenTablet	Maralixibat chloride	Netherlands	Authorised	2022
Livmarli 19 mg/ml, drankDrank	Maralixibat chloride	Netherlands	Authorised	2022
LIVMARLI 20 MG COMPRIMIDOS21,06 mg · Comprimido	Maralixibat chloride	Spain	Authorised	2026
Livmarli 20 mg, tablettenTablet	Maralixibat chloride	Netherlands	Authorised	2022
LIVMARLI 30 MG COMPRIMIDOS31,59 mg · Comprimido	Maralixibat chloride	Spain	Authorised	2026
Livmarli 30 mg, tablettenTablet	Maralixibat chloride	Netherlands	Authorised	2022
Livmarli 9,5 mg ml, drankDrank	Maralixibat chloride	Netherlands	Authorised	2022
LIVMARLI 9,5 MG/ML SOLUCION ORAL300 mg · Solución oral	Maralixibat chloride	Spain	Marketed	2023

Sources and licences

Country	Medicines	Current	Companies
Canada	6	6	Companies All medicines
Netherlands	6	6	Companies All medicines
Spain	5	5	Companies All medicines
United States	4	4	Companies All medicines
European Union (EMA)	1	1	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.

European Medicines Agency

Source: European Medicines Agency (EPAR data).

Licence: EMA reuse policy (source acknowledgement required)

Agencia Española de Medicamentos y Productos Sanitarios (CIMA)

Fuente de la información: AEMPS (CIMA).

Licence: AEMPS open data reuse with attribution

U.S. Food and Drug Administration (Drugs@FDA, openFDA)

Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.

Licence: Public domain (U.S. Government work)

Base de données publique des médicaments (ANSM, HAS, UNCAM)

Source: BDPM (ANSM, HAS, UNCAM).

Licence: Licence Ouverte v1.0

Health Canada, Canada

Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada

All 16 sources

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

BDPM / ANSM, HAS and UNCAM

BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

BDPM / ANSM, HAS and UNCAM, France

BDPM / ANSM, HAS and UNCAM, CIS_MITM.txt, published 13/10/2026, acquired 2026-10-25T22:15:46.803459+00:00; exact facts retained, no endorsement.

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

College ter Beoordeling van Geneesmiddelen

College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.

Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim

Läkemedelsverket, Sweden

Läkemedelsverket, Sweden, Läkemedelsprodukter, source extract 2026-10-20, acquired 2026-10-20T20:45:53.483733+00:00. Original cells retained; structured adaptation by Prognia. No regulator endorsement.

Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)

Wikidata

Wikidata (CC0)

Licence: CC0 1.0

Report an error or request removal Corrections from the company itself are welcome.

Mirum

Group structure

United States2

Netherlands1

Headquarters not stated2

Medicines

Know your medicines, with the sources.

Mirum

Group structure

United States2

Netherlands1

Headquarters not stated2

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Identifiers

Work with Prognia

Other big groups

United States: more companies

Group structure

🇺🇸United States2

🇳🇱Netherlands1

Headquarters not stated2

Medicines

Know your medicines, with the sources.

Group structure

🇺🇸United States2

🇳🇱Netherlands1

Headquarters not stated2

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Identifiers

Work with Prognia

United States2

Netherlands1

United States2

Netherlands1